Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2002 6
2003 16
2004 11
2005 8
2006 19
2007 13
2008 24
2009 15
2010 16
2011 13
2012 22
2013 29
2014 21
2015 13
2016 14
2017 16
2018 8
2019 4
2020 2
2021 5
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

255 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean lymphocyte OR Yttrium Y 90 Epratuzumab (832,024 results)?
Emerging B-Cell Therapies in Systemic Lupus Erythematosus.
Bag-Ozbek A, Hui-Yuen JS. Bag-Ozbek A, et al. Ther Clin Risk Manag. 2021 Jan 14;17:39-54. doi: 10.2147/TCRM.S252592. eCollection 2021. Ther Clin Risk Manag. 2021. PMID: 33488082 Free PMC article. Review.
This review discusses the current experience with B-cell-targeted therapies, including those targeting B-cell-surface antigens (rituximab, ocrelizumab, ofatumumab, obinutuzumab, obexelimab, epratuzumab, daratumumab), B-cell survival factors (belimumab, tabalumab, atacicept …
This review discusses the current experience with B-cell-targeted therapies, including those targeting B-cell-surface antigens (rituximab, o …
Immunotherapy in indolent Non-Hodgkin's Lymphoma.
Amhaz G, Bazarbachi A, El-Cheikh J. Amhaz G, et al. Leuk Res Rep. 2022 May 18;17:100325. doi: 10.1016/j.lrr.2022.100325. eCollection 2022. Leuk Res Rep. 2022. PMID: 35663281 Free PMC article.
Also multiple other agents emerged targeting different surface cell antigens like CD52 (alemtuzumab), CD22 (unconjugated epratuzumab and calicheamicin conjugated CMC-544 [inotuzumab ozogamicin]), CD80 (galiximab), CD2 (MEDI-507 [siplizumab]), CD30 (SGN-30 and MDX-060 [irat …
Also multiple other agents emerged targeting different surface cell antigens like CD52 (alemtuzumab), CD22 (unconjugated epratuzumab
(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.
Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, Huguet F, Hunault M, Marcais A, Gaschet J, Cherel M, Guillaume T, Delaunay J, Peterlin P, Eveillard M, Thomas X, Ifrah N, Lapusan S, Bodet-Milin C, Barbet J, Faivre-Chauvet A, Ferrer L, Bene MC, Le Houerou C, Goldenberg DM, Wegener WA, Kraeber-Bodéré F. Chevallier P, et al. Lancet Haematol. 2015 Mar;2(3):e108-17. doi: 10.1016/S2352-3026(15)00020-4. Epub 2015 Feb 25. Lancet Haematol. 2015. PMID: 26687796 Clinical Trial.
We aimed to assess the feasibility, tolerability, dosimetry, and efficacy of yttrium-90-labelled anti-CD22 epratuzumab tetraxetan ((90)Y-DOTA-epratuzumab) radioimmunotherapy in refractory or relapsed CD22-positive B-cell acute lymphoblast …
We aimed to assess the feasibility, tolerability, dosimetry, and efficacy of yttrium-90-labelled anti-CD22 epratuzumab
Clinical trials in systemic lupus erythematosus: the dilemma-Why have phase III trials failed to confirm the promising results of phase II trials?
Lorenzo-Vizcaya A, Isenberg DA. Lorenzo-Vizcaya A, et al. Ann Rheum Dis. 2023 Feb;82(2):169-174. doi: 10.1136/ard-2022-222839. Epub 2022 Oct 6. Ann Rheum Dis. 2023. PMID: 36202589 Review.
Thus, trials with many drugs against different targets, such as CD22, IL-12 and IL-23 or tyrosine kinases, have been carried out in recent years.A frustrating feature of some of the biologic drugs used to treat SLE has been the reporting of successful phase II trials followed by …
Thus, trials with many drugs against different targets, such as CD22, IL-12 and IL-23 or tyrosine kinases, have been carried out in recent y …
Radioimmunotherapy in follicular lymphoma.
Illidge T, Morschhauser F. Illidge T, et al. Best Pract Res Clin Haematol. 2011 Jun;24(2):279-93. doi: 10.1016/j.beha.2011.03.005. Epub 2011 May 12. Best Pract Res Clin Haematol. 2011. PMID: 21658624 Review.
For more than a decade clinical RIT of FL has been dominated by targeting the CD20 antigen and a number of pivotal clinical studies have resulted in the approval by the US FDA (Food and Drug Administration) of two radioimmunconjugates, (131)I-tositumomab (Bexxar) and (90) …
For more than a decade clinical RIT of FL has been dominated by targeting the CD20 antigen and a number of pivotal clinical studies have res …
Epratuzumab for systemic lupus erythematosus.
Wallace DJ, Goldenberg DM. Wallace DJ, et al. Lupus. 2013 Apr;22(4):400-5. doi: 10.1177/0961203312469692. Lupus. 2013. PMID: 23553783 Review.
Epratuzumab (EMab, UCB, Immunomedics) is a humanized monoclonal antibody targeting CD22 that is being studied in clinical trials for patients with a variety of rheumatic and hematologic conditions, including systemic lupus erythematosus (SLE). ...
Epratuzumab (EMab, UCB, Immunomedics) is a humanized monoclonal antibody targeting CD22 that is being studied in clinical trials for
Consolidation anti-CD22 fractionated radioimmunotherapy with (90)Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.
Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P. Kraeber-Bodere F, et al. Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8. Lancet Haematol. 2017. PMID: 27964867 Clinical Trial.
We aimed to assess activity and toxicity of fractionated radioimmunotherapy using anti-CD22 (90)Y-epratuzumab tetraxetan as consolidation after front-line induction chemoimmunotherapy in untreated elderly patients with diffuse large B-cell lymphoma. ...One pa …
We aimed to assess activity and toxicity of fractionated radioimmunotherapy using anti-CD22 (90)Y-epratuzumab tetraxeta …
Epratuzumab for the treatment of systemic lupus erythematosus.
Geh D, Gordon C. Geh D, et al. Expert Rev Clin Immunol. 2018 Apr;14(4):245-258. doi: 10.1080/1744666X.2018.1450141. Epub 2018 Mar 20. Expert Rev Clin Immunol. 2018. PMID: 29542345 Review.
New treatments are needed for the management of active lupus. Epratuzumab a humanized IgG1 monoclonal antibody that targets CD22 resulting in selective B cell modulation that has been considered a potential treatment for SLE. Areas covered: Summary of the relevant pathogen …
New treatments are needed for the management of active lupus. Epratuzumab a humanized IgG1 monoclonal antibody that targets CD22 resu …
255 results